Integrated Diagnostics Holdings annual stock-based compensation
2021
2022
2023
2024
2025
Integrated Diagnostics Holdings Stock-Based Compensation Growth & History (IDHC)
Integrated Diagnostics Holdings's stock-based compensation was E£1.4M for fiscal 2025.
View full Integrated Diagnostics Holdings company overviewIntegrated Diagnostics Holdings annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | E£1.4M | −E£3.3M | −70.49% |
| 2024 | 2024-12-31 | E£4.7M | −E£2.4M | −34.02% |
| 2023 | 2023-12-31 | E£7.1M | −E£501,000 | −6.60% |
| 2022 | 2022-12-31 | E£7.6M | E£6.7M | +776.91% |
| 2021 | 2021-12-31 | E£866,000 | — | — |
Integrated Diagnostics Holdings stock-based compensation trends
Between the periods ended 2021-12-31 and 2025-12-31, Integrated Diagnostics Holdings's stock-based compensation increased from E£866,000 to E£1.4M, a change of E£515,000.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
reported stock-based compensation
TickerStat standardizes share-based compensation reported in company official filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Integrated Diagnostics Holdings source filings ↗